Cargando…

Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study

BACKGROUND: Despite intensive insulin treatment, many patients with type-1 diabetes (T1DM) have longstanding inadequate glycaemic control. Metformin is an oral hypoglycaemic agent that improves insulin action in patients with type-2 diabetes. We investigated the effect of a one-year treatment with m...

Descripción completa

Detalles Bibliográficos
Autores principales: Lund, Søren Søgaard, Tarnow, Lise, Astrup, Anne Sofie, Hovind, Peter, Jacobsen, Peter Karl, Alibegovic, Amra Ciric, Parving, Ida, Pietraszek, Lotte, Frandsen, Merete, Rossing, Peter, Parving, Hans-Henrik, Vaag, Allan Arthur
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566605/
https://www.ncbi.nlm.nih.gov/pubmed/18852875
http://dx.doi.org/10.1371/journal.pone.0003363
_version_ 1782159958047981568
author Lund, Søren Søgaard
Tarnow, Lise
Astrup, Anne Sofie
Hovind, Peter
Jacobsen, Peter Karl
Alibegovic, Amra Ciric
Parving, Ida
Pietraszek, Lotte
Frandsen, Merete
Rossing, Peter
Parving, Hans-Henrik
Vaag, Allan Arthur
author_facet Lund, Søren Søgaard
Tarnow, Lise
Astrup, Anne Sofie
Hovind, Peter
Jacobsen, Peter Karl
Alibegovic, Amra Ciric
Parving, Ida
Pietraszek, Lotte
Frandsen, Merete
Rossing, Peter
Parving, Hans-Henrik
Vaag, Allan Arthur
author_sort Lund, Søren Søgaard
collection PubMed
description BACKGROUND: Despite intensive insulin treatment, many patients with type-1 diabetes (T1DM) have longstanding inadequate glycaemic control. Metformin is an oral hypoglycaemic agent that improves insulin action in patients with type-2 diabetes. We investigated the effect of a one-year treatment with metformin versus placebo in patients with T1DM and persistent poor glycaemic control. METHODOLOGY/PRINCIPAL FINDINGS: One hundred patients with T1DM, preserved hypoglycaemic awareness and HaemoglobinA(1c) (HbA(1c)) ≥8.5% during the year before enrolment entered a one-month run-in on placebo treatment. Thereafter, patients were randomized (baseline) to treatment with either metformin (1 g twice daily) or placebo for 12 months (double-masked). Patients continued ongoing insulin therapy and their usual outpatient clinical care. The primary outcome measure was change in HbA(1c) after one year of treatment. At enrolment, mean (standard deviation) HbA(1c) was 9.48% (0.99) for the metformin group (n = 49) and 9.60% (0.86) for the placebo group (n = 51). Mean (95% confidence interval) baseline-adjusted differences after 12 months with metformin (n = 48) versus placebo (n = 50) were: HbA(1c), 0.13% (−0.19; 0.44), p = 0.422; Total daily insulin dose, −5.7 U/day (−8.6; −2.9), p<0.001; body weight, −1.74 kg (−3.32; −0.17), p = 0.030. Minor and overall major hypoglycaemia was not significantly different between treatments. Treatments were well tolerated. CONCLUSIONS/SIGNIFICANCE: In patients with poorly controlled T1DM, adjunct metformin therapy did not provide any improvement of glycaemic control after one year. Nevertheless, adjunct metformin treatment was associated with sustained reductions of insulin dose and body weight. Further investigations into the potential cardiovascular-protective effects of metformin therapy in patients with T1DM are warranted. TRIAL REGISTRATION: ClinicalTrials.gov NCT00118937
format Text
id pubmed-2566605
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-25666052008-10-11 Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study Lund, Søren Søgaard Tarnow, Lise Astrup, Anne Sofie Hovind, Peter Jacobsen, Peter Karl Alibegovic, Amra Ciric Parving, Ida Pietraszek, Lotte Frandsen, Merete Rossing, Peter Parving, Hans-Henrik Vaag, Allan Arthur PLoS One Research Article BACKGROUND: Despite intensive insulin treatment, many patients with type-1 diabetes (T1DM) have longstanding inadequate glycaemic control. Metformin is an oral hypoglycaemic agent that improves insulin action in patients with type-2 diabetes. We investigated the effect of a one-year treatment with metformin versus placebo in patients with T1DM and persistent poor glycaemic control. METHODOLOGY/PRINCIPAL FINDINGS: One hundred patients with T1DM, preserved hypoglycaemic awareness and HaemoglobinA(1c) (HbA(1c)) ≥8.5% during the year before enrolment entered a one-month run-in on placebo treatment. Thereafter, patients were randomized (baseline) to treatment with either metformin (1 g twice daily) or placebo for 12 months (double-masked). Patients continued ongoing insulin therapy and their usual outpatient clinical care. The primary outcome measure was change in HbA(1c) after one year of treatment. At enrolment, mean (standard deviation) HbA(1c) was 9.48% (0.99) for the metformin group (n = 49) and 9.60% (0.86) for the placebo group (n = 51). Mean (95% confidence interval) baseline-adjusted differences after 12 months with metformin (n = 48) versus placebo (n = 50) were: HbA(1c), 0.13% (−0.19; 0.44), p = 0.422; Total daily insulin dose, −5.7 U/day (−8.6; −2.9), p<0.001; body weight, −1.74 kg (−3.32; −0.17), p = 0.030. Minor and overall major hypoglycaemia was not significantly different between treatments. Treatments were well tolerated. CONCLUSIONS/SIGNIFICANCE: In patients with poorly controlled T1DM, adjunct metformin therapy did not provide any improvement of glycaemic control after one year. Nevertheless, adjunct metformin treatment was associated with sustained reductions of insulin dose and body weight. Further investigations into the potential cardiovascular-protective effects of metformin therapy in patients with T1DM are warranted. TRIAL REGISTRATION: ClinicalTrials.gov NCT00118937 Public Library of Science 2008-10-09 /pmc/articles/PMC2566605/ /pubmed/18852875 http://dx.doi.org/10.1371/journal.pone.0003363 Text en Lund et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Lund, Søren Søgaard
Tarnow, Lise
Astrup, Anne Sofie
Hovind, Peter
Jacobsen, Peter Karl
Alibegovic, Amra Ciric
Parving, Ida
Pietraszek, Lotte
Frandsen, Merete
Rossing, Peter
Parving, Hans-Henrik
Vaag, Allan Arthur
Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study
title Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study
title_full Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study
title_fullStr Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study
title_full_unstemmed Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study
title_short Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study
title_sort effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. a randomized study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566605/
https://www.ncbi.nlm.nih.gov/pubmed/18852875
http://dx.doi.org/10.1371/journal.pone.0003363
work_keys_str_mv AT lundsørensøgaard effectofadjunctmetformintreatmentinpatientswithtype1diabetesandpersistentinadequateglycaemiccontrolarandomizedstudy
AT tarnowlise effectofadjunctmetformintreatmentinpatientswithtype1diabetesandpersistentinadequateglycaemiccontrolarandomizedstudy
AT astrupannesofie effectofadjunctmetformintreatmentinpatientswithtype1diabetesandpersistentinadequateglycaemiccontrolarandomizedstudy
AT hovindpeter effectofadjunctmetformintreatmentinpatientswithtype1diabetesandpersistentinadequateglycaemiccontrolarandomizedstudy
AT jacobsenpeterkarl effectofadjunctmetformintreatmentinpatientswithtype1diabetesandpersistentinadequateglycaemiccontrolarandomizedstudy
AT alibegovicamraciric effectofadjunctmetformintreatmentinpatientswithtype1diabetesandpersistentinadequateglycaemiccontrolarandomizedstudy
AT parvingida effectofadjunctmetformintreatmentinpatientswithtype1diabetesandpersistentinadequateglycaemiccontrolarandomizedstudy
AT pietraszeklotte effectofadjunctmetformintreatmentinpatientswithtype1diabetesandpersistentinadequateglycaemiccontrolarandomizedstudy
AT frandsenmerete effectofadjunctmetformintreatmentinpatientswithtype1diabetesandpersistentinadequateglycaemiccontrolarandomizedstudy
AT rossingpeter effectofadjunctmetformintreatmentinpatientswithtype1diabetesandpersistentinadequateglycaemiccontrolarandomizedstudy
AT parvinghanshenrik effectofadjunctmetformintreatmentinpatientswithtype1diabetesandpersistentinadequateglycaemiccontrolarandomizedstudy
AT vaagallanarthur effectofadjunctmetformintreatmentinpatientswithtype1diabetesandpersistentinadequateglycaemiccontrolarandomizedstudy